Safety and Efficacy of Donafenib in Patients With Advanced Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2016-10-30
Target enrollment:
Participant gender:
Summary
This phase IB study of donafenib, an oral multikinase inhibitor that targets Raf kinase and
receptor tyrosine kinases, is to assess toxicity,efficacy and pharmacokinetics in patients
wiht advanced hepatocellular carcinoma (HCC) .